Literature DB >> 17576784

Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue.

Ronald F van Vollenhoven.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17576784      PMCID： PMC1955116          DOI： 10.1136/ard.2007.069872

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  26 in total

1.  Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy.

Authors:  J A Gómez-Puerta; R Sanmartí; J R Rodríguez-Cros; J D Cañete
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

2.  Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?

Authors:  Y Yazici; D Erkan
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

3.  Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect.

Authors:  R F van Vollenhoven; S Brannemark; L Klareskog
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

4.  Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.

Authors:  Ennio Giulio Favalli; Marco Arreghini; Cristina Arnoldi; Benedetta Panni; Antonio Marchesoni; Sergio Tosi; Irene Pontikaki
Journal:  Arthritis Rheum       Date:  2004-04-15

5.  Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

Authors:  Elisabeth Hjardem; Mikkel Østergaard; Jan Pødenphant; Ulrik Tarp; Lis Smedegaard Andersen; Jette Bing; Elisabeth Peen; Hanne Merete Lindegaard; Vibeke Stevenius Ringsdal; Anne Rødgaard; Jens Skøt; Annette Hansen; Hans Henrik Mogensen; Janne Unkerskov; Merete Lund Hetland
Journal:  Ann Rheum Dis       Date:  2007-03-27       Impact factor: 19.103

6.  Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry.

Authors:  Ronald F van Vollenhoven; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2003-06

7.  Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?

Authors:  Herbert T S Ang; Simon Helfgott
Journal:  J Rheumatol       Date:  2003-11       Impact factor: 4.666

8.  The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.

Authors:  Karen E Hansen; Julie P Hildebrand; Mark C Genovese; John J Cush; Supen Patel; David A Cooley; Stanley B Cohen; Ronald E Gangnon; Michael H Schiff
Journal:  J Rheumatol       Date:  2004-06       Impact factor: 4.666

9.  [Etanercept--infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti TNFalpha].

Authors:  O Brocq; Y Plubel; V Breuil; C Grisot; P Flory; A Mousnier; L Euller-Ziegler
Journal:  Presse Med       Date:  2002-11-23       Impact factor: 1.228

10.  Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense.

Authors:  R van Vollenhoven; A Harju; S Brannemark; L Klareskog
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103
View more
  21 in total

Review 1.  Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.

Authors:  Piergiorgio Neri; Manuela Zucchi; Pia Allegri; Marta Lettieri; Cesare Mariotti; Alfonso Giovannini
Journal:  Int Ophthalmol       Date:  2011-02-02       Impact factor: 2.031

Review 2.  Treatment of rheumatoid arthritis: state of the art 2009.

Authors:  Ronald F van Vollenhoven
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

3.  [Switching within the active ingredient group or changing the mechanism of action. Data situation by failure of the first line biologic].

Authors:  A Rubbert-Roth
Journal:  Z Rheumatol       Date:  2015-06       Impact factor: 1.372

Review 4.  Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis.

Authors:  Kenneth S Rosenthal; Katalin Mikecz; Harold L Steiner; Tibor T Glant; Alison Finnegan; Roy E Carambula; Daniel H Zimmerman
Journal:  Expert Rev Vaccines       Date:  2015-03-18       Impact factor: 5.217

5.  Structural basis for tumor necrosis factor blockade with the therapeutic antibody golimumab.

Authors:  Masatsugu Ono; Shoichiro Horita; Yumi Sato; Yayoi Nomura; So Iwata; Norimichi Nomura
Journal:  Protein Sci       Date:  2018-04-17       Impact factor: 6.725

6.  Adalimumab (humira™) in ophthalmology: a review of the literature.

Authors:  Piergiorgio Neri; Marta Lettieri; Cinzia Fortuna; Manuela Zucchi; Mara Manoni; Silvia Celani; Alfonso Giovannini
Journal:  Middle East Afr J Ophthalmol       Date:  2010-10

Review 7.  Genetics of rheumatoid arthritis - a comprehensive review.

Authors:  Júlia Kurkó; Timea Besenyei; Judit Laki; Tibor T Glant; Katalin Mikecz; Zoltán Szekanecz
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

Review 8.  Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.

Authors:  Joachim R Kalden; Hendrik Schulze-Koops
Journal:  Nat Rev Rheumatol       Date:  2017-11-21       Impact factor: 20.543

Review 9.  Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.

Authors:  Joseph R Lutt; Atul Deodhar
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial.

Authors:  Susanne J J Claessen; Johanna M W Hazes; Margriet A M Huisman; Derkjen van Zeben; Jolanda J Luime; Angelique E A M Weel
Journal:  BMC Musculoskelet Disord       Date:  2009-06-18       Impact factor: 2.362
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.